|
Budget allocation for DoP jumps two fold to Rs. 2,244 crore with impetus to PLI schemes
|
|
Gireesh Babu, New Delhi
February 07 , 2022
|
|
|
The Union Budget 2022-23 has estimated a significant hike in total allocation to the Department of Pharmaceuticals (DoP) for the upcoming financial year, at Rs. 2,244 crore of which a majority is expected to back the Central Sector Schemes with prominence to the production linked incentive (PLI) schemes in the sector.
The actual budget spending on the DoP was of Rs. 456.01 crore in 2020-21, and the revised budget estimate was at Rs. 823.11 crore for the year 2021-22. Compared to this revised budget estimate, the allocation for the year 2022-23 is almost a two fold jump.
Of the total budget allocation for the year 2022-23, around Rs. 1,629 crore is towards the five PLI schemes in the sector, with major allocation towards bulk drug parks and PLI scheme for bulk drugs, according to the Ministry of Finance.
The allocation for promotion of bulk drug parks is estimated at Rs. 900 crore, as compared to the Rs. 36.24 crore spent in the previous year. PLI scheme for promotion of domestic manufacturing of critical key starting materials (KSMs)/drug intermediates (DI) and active pharmaceutical ingredients (APIs) in India will get a Rs. 390 crore estimated allocation, as compared to the Rs. 2.79 crore spent for the scheme last year.
Promotion of Medical Device Parks has an allocation of Rs. 120 crore, as compared to the Rs. 137.02 crore under the revised budget estimate for the year 2021-22, while the PLI scheme for domestic manufacturing of medical devices has an allocation of Rs. 216 crore for 2022-23, as against Rs. 3.31 crore under the revised budget estimate for the previous year.
The PLI scheme for pharmaceuticals will have an allocation of Rs. 3 crore, similar to what it was in the previous year.
The National Pharmaceutical Pricing Authority (NPPA) will see a marginal increase in allocation to Rs. 17.79 crore during the year 2022-23 as per the estimate, compared to the Rs. 14.01 crore spent under the revised budget for 2021-22. National Institutes of Pharmaceutical Education and Research (NIPERs) will have an allocation of Rs. 350 crore, similar to what has been spent in the previous year.
Jan Aushadhi Scheme has seen an allocation of Rs. 72.5 crore, a marginal increase from Rs. 68.50 crore spent as per the revised budget estimate for the previous year.
Rs. 100 crore has been allocated for various projects under the header of development of pharmaceutical industry, of which Rs. 62 crore will go to Pharmaceutical Technology Upgradation Assistance Scheme (PTUAS), another Rs. 36 crore to Assistance to Pharmaceutical Industry for Common Facilities (API-CF)/cluster development and the rest of Rs. 2 crore to Pharmaceutical Promotion and Development Scheme (PPDS). Last year, there was hardly any allocation under the header.
Under the other Central sector expenditure, NIPERs will get a Rs. 45 crore, as against Rs. 22 crore last year. The assistance to Public Sector Undertakings under the DoP, which saw a capital expenditure of Rs. 148 crore as per the revised estimate for 2021-22, will be Rs. 5.30 crore for the year 2022-23. The total investment, including internal and extra budgetary resources for the seven PSUs was Rs. 178 crore in 2021-22, which is estimated to be Rs. 38.30 crore in 2022-23.
|
|
|
|
|
|
|
|
TOPICS
|
That foods might provide therapeutic benefits is clearly not a new concept. ...
|
|
|
|
|